The clock is ticking for the medical-testing startup to rectify these issues.
The bad news keeps on coming for Theranos, the medical-testing startup with an eye-popping $10 billion valuation. U.S. government regulators said in a public letter to the company today that its deficiencies pose “immediate jeopardy to patient health and safety.”
